# Amphista Therapeutics Ltd: Phase 1 study started recruiting, 54 planned (Acute Myeloid Leukaemia, High Risk Myelodysplastic Syndrome)

**Score:** 55/100

| Field | Value |
|---|---|
| Sponsor | Amphista Therapeutics Ltd |
| Sponsor type | Industry (pharma, biotech, medtech) |
| Study | Phase 1 Open-label Study of AMX-883 Alone in Participants With AML and High-risk MDS and in Combination in Participants With AML |
| NCT ID | NCT07723703 |
| Phase | Phase 1 |
| Status | recruiting |
| Conditions | Acute Myeloid Leukaemia; High Risk Myelodysplastic Syndrome |
| Intervention types | drug |
| Target enrollment | 54 |
| Site countries | United States |
| Posted | 2026-07-23 |
| Planned start | 2026-09-16 |
| Event | Started recruiting |
| Event date | 2026-09-16 |
| Last update posted | 2026-10-15 |

## Why this score
- Industry sponsor (buys outsourced services).
- Just started recruiting: sites, recruitment and supply are active.

Source: ClinicalTrials.gov (U.S. National Library of Medicine) API v2 (https://clinicaltrials.gov/study/NCT07723703). Last refreshed: 2026-11-05T08:46:16.625Z.
From public ClinicalTrials.gov registrations. Sponsor and study level only: we never list investigators, contacts or participants. A registration describes a planned study and can change. Status changes are read from each study's current status, actual dates and latest posted update, not a full change history, so an update can be a correction rather than a new change. Verify on ClinicalTrials.gov.